Fund moves

Regeneron Pharmaceuticals (REGN): Candriam S.C.A. added to its stake +9,286 shares

Candriam S.C.A. added to its stake in Regeneron Pharmaceuticals, per its Q2 2026 13F.

196K
Shares reported · +9,286 vs prior quarter
0.55%
Disclosed portfolio weight
$122M
Reported value
Holdings as of
Jun 30, 2026
Filed
Aug 13, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 27, 2026CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
  2. Jul 2, 2026InsiderDirector sold ~$130K of REGN shares in the open market
  3. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
  4. Jul 16, 2026Court · District Court, S.D. New YorkSecurities lawsuit filed: In re REGENERON PHARMACEUTICALS INC. SECURITIES LITIGATION
  5. Jul 28, 2026FDARecall: Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pha…
  6. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
  7. Aug 10, 2026Insider · 2 peopleInsiders: 2 sales (~$960K)

What came next

  1. Aug 19, 2026FDAFDA drug approval: Pasatru
  2. Sep 2, 2026Insider · 2 peopleInsiders: 2 sales (~$1.4M)
  3. Sep 3, 2026InsiderOfficer sold ~$970K of REGN shares in the open market
  4. Sep 23, 2026Court · District Court, S.D. New YorkSecurities lawsuit filed: Hopkinson v. Regeneron Pharmaceuticals, Inc.
  5. Sep 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated…”
  6. Oct 1, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)
  7. Oct 1, 2026Government · Federal Register noticeAdvisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal
  8. Oct 14, 2026Insider · 1 personInsiders: 27 sales (~$3.2M)
  9. Oct 30, 2026Company filing · Form 8-K · ResultsReported its results
  10. Oct 30, 2026Insider · 3 peopleInsiders: 3 sales (~$3.0M)
  11. Nov 2, 2026Insider · 3 peopleInsiders: 17 sales (~$32.3M)
  12. Nov 3, 2026Insider · 1 personInsiders: 2 sales (~$7.2M)
  13. Nov 4, 2026Insider · 1 personInsiders: 8 sales (~$3.8M)
  14. Nov 16, 2026Insider · 1 personInsiders: 13 sales (~$544K)
  15. Nov 17, 2026Insider · 1 personInsiders: 3 sales (~$858K)
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 110 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

How this filing works

Explore the data

Common questions

What does this filing report about Regeneron Pharmaceuticals (REGN) stock?

Candriam S.C.A. added to its stake in Regeneron Pharmaceuticals, per its Q2 2026 13F. Now 196K shares, $122M reported value, 0.55% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Jun 30, 2026. Filed: Aug 13, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Regeneron Pharmaceuticals recently?

For Regeneron Pharmaceuticals, OQRO holds 110 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the REGN page.

Does this mean REGN stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Regeneron Pharmaceuticals

Everything OQRO holds on this company is on its REGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data